Rafael Amado
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Allogene CFO Departure Comes Amid CAR-T Sector Safety Concerns. Allogene announced that Chief Financial Officer Geoffrey Parker will retire effective November 6, marking a leadership transition at a challenging time for the company. The timing coincides with broader scrutiny of CAR-T therapies for autoimmune conditions after competing trials from Novartis and Bristol Myers were paused over safety concerns. On the clinical front, the company indicated that if its minimal residual disease data holds, it could represent a significant shift in its business outlook. The stock has traded within a $1.04 to $4.46 range over the past year.
Transaction History
| ZLAB | ▼ Sell | Open Market | 2,739 | $56K | 4/6/2026 | View on chart |
| ZLAB | ▲ Buy | Option Exercise | 5,391 | — | 4/2/2026 | View on chart |
| ZLAB | ▼ Sell | Open Market | 9,910 | $202K | 4/2/2026 | View on chart |
| ZLAB | ▲ Buy | Option Exercise | 19,523 | — | 4/1/2026 | View on chart |
| ZLAB | ▼ Sell | Open Market | 2,957 | $55K | 3/13/2026 | View on chart |
| ZLAB | ▲ Buy | Option Exercise | 5,323 | — | 3/12/2026 | View on chart |
| ZLAB | ▼ Sell | Open Market | 10,000 | $174K | 3/3/2026 | View on chart |
| ZLAB | ▼ Sell | Open Market | 10,787 | $188K | 12/31/2025 | View on chart |
| ZLAB | ▲ Buy | Option Exercise | 21,000 | — | 12/30/2025 | View on chart |
| ZLAB | ▼ Sell | Open Market | 3,000 | $105K | 8/8/2025 | View on chart |
| ZLAB | ▼ Sell | Open Market | 3,029 | $100K | 4/4/2025 | View on chart |
| ZLAB | ▲ Buy | Option Exercise | 5,391 | — | 4/3/2025 | View on chart |
| ZLAB | ▼ Sell | Open Market | 7,541 | $271K | 4/2/2025 | View on chart |
| ZLAB | ▲ Buy | Option Exercise | 19,523 | — | 4/1/2025 | View on chart |
| ZLAB | ▼ Sell | Open Market | 3,000 | $115K | 3/17/2025 | View on chart |
| ZLAB | ▼ Sell | Open Market | 7,583 | $199K | 12/31/2024 | View on chart |
| ZLAB | ▲ Buy | Option Exercise | 21,000 | — | 12/30/2024 | View on chart |
| ZLAB | ▼ Sell | Open Market | 3,115 | $50K | 8/12/2024 | View on chart |
| ZLAB | ▼ Sell | Open Market | 1,952 | $31K | 4/4/2024 | View on chart |
| ZLAB | ▲ Buy | Option Exercise | 5,391 | $86K | 4/3/2024 | View on chart |
| ZLAB | ▼ Sell | Open Market | 2,544 | $48K | 3/15/2024 | View on chart |
| ZLAB | ▼ Sell | Open Market | 19,363 | $509K | 1/2/2024 | View on chart |
| ZLAB | ▲ Buy | Option Exercise | 21,000 | — | 12/29/2023 | View on chart |
| ZLAB | ▲ Buy | Option Exercise | 21,000 | — | 12/29/2023 | View on chart |
| ZLAB | ▲ Buy | Grant | 126,000 | $0 | 12/30/2022 | View on chart |
| ALLO | ▲ Buy | Grant | 19,120 | $0 | 10/7/2022 | View on chart |
| ALLO | ▼ Sell | Tax Withholding | 8,464 | $100K | 10/7/2022 | View on chart |
| ALLO | ▼ Sell | Tax Withholding | 8,968 | $99K | 10/3/2022 | View on chart |
| ALLO | ▼ Sell | Open Market | 2,000 | $24K | 8/2/2022 | View on chart |
| ALLO | ▼ Sell | Open Market | 2,000 | $23K | 7/5/2022 | View on chart |
| ALLO | ▼ Sell | Open Market | 2,000 | $22K | 6/21/2022 | View on chart |
| ALLO | ▼ Sell | Open Market | 11,500 | $85K | 5/19/2022 | View on chart |
| ALLO | ▲ Buy | Grant | 237,358 | $0 | 3/23/2022 | View on chart |
| ALLO | ▼ Sell | Open Market | 5,169 | $40K | 3/15/2022 | View on chart |
| ALLO | ▼ Sell | Open Market | 11,507 | $280K | 10/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Zai Lab Releases Q2 2026 Earnings and Call Transcript
Zai Lab has published its second-quarter 2026 financial results along with the full earnings call transcript. This update provides investors with the latest details on the company's performance and strategic outlook. The stock is currently trading within its 52-week range, with analysts maintaining a wide target price spread.
Zai Lab Releases Q2 2026 Earnings and Call Transcript. Zai Lab has published its second-quarter 2026 financial results along with the full earnings call transcript. This update provides investors with the latest details on the company's performance and strategic outlook. The stock is currently trading within its 52-week range, with analysts maintaining a wide target price spread.